Estimated read time: 2-3 minutes
NEW YORK (AP) — Stocks are climbing in afternoon trading on Wall Street. They're getting a boost from today's Labor Department report showing that the economy added 223,000 jobs in April and the unemployment rate fell to 5.4 percent. The Dow Jones industrial average has been up more than 250 points.
UNDATED (AP) — Triple-A expects more than 37 million Americans to travel for Memorial Day, the most since 2005. The auto club says the number of Americans taking a trip of 50 miles or more will rise 4.7 percent to 37.2 million, and nearly nine out of 10 travelers, or 33 million, will drive to their destination. Gasoline should be about a dollar cheaper this Memorial Day. Last Memorial Day the average price for a gallon of gas was $3.66.
DETROIT (AP) — Fiat Chrysler is asking a judge for a new trial after a jury awarded $150 million to the family of a Georgia boy killed in a crash and fire involving a Jeep. The company says the damage award in the death of 4-year-old Remington Walden is excessive and illegal. The boy burned to death in 2012 when a 1999 Jeep Grand Cherokee was hit from behind and its rear-mounted gas tank ruptured. Last month the jury ruled that Fiat Chrysler was 99 percent responsible.
NEW YORK (AP) — Baby's Dream Inc. is recalling about 4,600 cribs and assorted pieces of furniture because they contain excessive levels of lead paint. The recalled cribs and furniture were sold in a vintage gray paint finish under the Brie, Braxton, Heritage, Everything Nice and Legendary collections. The items were made in Chile and sold between March 2014 and March 2015 at specialty furniture stores and at BabysDream.com.
WASHINGTON (AP) — Federal health regulators say an experimental combination drug for cystic fibrosis developed by Vertex Pharmaceuticals helped improve breathing in patients with the deadly inherited disease. But the Food and Drug Administration says in an online review that the benefit was small and it not clear the addition of a second ingredient adds to the pill's effectiveness. The experimental drug is the company's follow-up to its breakthrough treatment, Kalydeco, which the FDA approved in 2012.